4/16
05:43 pm
teva
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Low
Report
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
4/16
11:53 am
teva
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies [Yahoo! Finance]
Low
Report
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies [Yahoo! Finance]
4/16
08:20 am
teva
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets [Yahoo! Finance]
Low
Report
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets [Yahoo! Finance]
4/16
08:00 am
teva
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Low
Report
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
4/11
08:48 am
teva
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China [Yahoo! Finance]
Low
Report
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China [Yahoo! Finance]
4/11
08:30 am
teva
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Low
Report
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
4/9
04:37 pm
teva
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 [Yahoo! Finance]
Low
Report
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 [Yahoo! Finance]
4/9
04:30 pm
teva
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Low
Report
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
4/8
01:17 pm
teva
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria [Yahoo! Finance]
Low
Report
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria [Yahoo! Finance]
4/8
01:15 pm
teva
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria [Yahoo! Finance]
Low
Report
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria [Yahoo! Finance]
4/7
08:07 am
teva
Generic Medicine Market To Reach USD 818.3 Billion By 2032, Says DataHorizzon Research [Yahoo! Finance]
Low
Report
Generic Medicine Market To Reach USD 818.3 Billion By 2032, Says DataHorizzon Research [Yahoo! Finance]
4/6
01:08 pm
teva
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 [Yahoo! Finance]
Low
Report
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 [Yahoo! Finance]
4/6
01:00 pm
teva
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
Low
Report
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
4/4
08:55 am
teva
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate [Yahoo! Finance]
Low
Report
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate [Yahoo! Finance]
4/4
08:30 am
teva
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Low
Report
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
4/3
11:24 am
teva
Nanomedicine Market Size Expected to Reach USD 562.93 Bn by 2032 [Yahoo! Finance]
Low
Report
Nanomedicine Market Size Expected to Reach USD 562.93 Bn by 2032 [Yahoo! Finance]
4/3
08:24 am
teva
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals [Yahoo! Finance]
Medium
Report
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals [Yahoo! Finance]
4/1
08:35 am
teva
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-'248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement [Yahoo! Financ
Low
Report
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-'248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement [Yahoo! Financ
4/1
08:30 am
teva
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
Low
Report
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
3/26
02:10 pm
teva
Global Montelukast Sodium Market Size To Worth USD 7.1 Billion By 2033 | CAGR of 5.64% [Yahoo! Finance]
Low
Report
Global Montelukast Sodium Market Size To Worth USD 7.1 Billion By 2033 | CAGR of 5.64% [Yahoo! Finance]
3/26
12:52 pm
teva
Asia Pacific Alopecia Treatment Market Forecasts 2023-2030, Featuring Teva Pharmaceutical, Merck, Johnson & Johnson, Cipla, Cellmid, The Himalaya Drug Company, Taisho Pharmaceutical and Shiseido [Yahoo! Finance]
Low
Report
Asia Pacific Alopecia Treatment Market Forecasts 2023-2030, Featuring Teva Pharmaceutical, Merck, Johnson & Johnson, Cipla, Cellmid, The Himalaya Drug Company, Taisho Pharmaceutical and Shiseido [Yahoo! Finance]
3/26
06:44 am
teva
Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership [Yahoo! Finance]
Low
Report
Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership [Yahoo! Finance]
3/24
07:38 pm
teva
25 Countries with the Lowest Fertility Rates [Yahoo! Finance]
Low
Report
25 Countries with the Lowest Fertility Rates [Yahoo! Finance]
3/13
01:55 pm
teva
Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell's Supervisory Board [Yahoo! Finance]
Low
Report
Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell's Supervisory Board [Yahoo! Finance]
3/11
12:35 pm
teva
Global Fibrate Drugs Market Report 2024: A $5.14 Billion Market by 2034, Rising from S2.95 Billion in 2023 [Yahoo! Finance]
Low
Report
Global Fibrate Drugs Market Report 2024: A $5.14 Billion Market by 2034, Rising from S2.95 Billion in 2023 [Yahoo! Finance]